Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance |
Abstract
|
Heather Cartwright |
|
Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions |
Abstract
|
Heather Cartwright |
|
Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics |
Abstract
|
Heather Cartwright |
|
Constellation and Genentech Form Broad Epigenetics Collaboration with Buyout Option |
Abstract
|
Heather Cartwright |
|
Shire Licenses Sangamo’s Genome-Editing Technology for Haemophilia and Other Monogenic Diseases |
Abstract
|
Heather Cartwright |
|
Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal |
Abstract
|
Heather Cartwright |
|
Merck KGaA Boosts its Late-Stage Pipeline by Licensing Threshold’s Hypoxia-Targeted Cancer Drug |
Abstract
|
Heather Cartwright |
|
Enanta Pharmaceuticals Partners its Lead HCV NS5A Inhibitor with Novartis |
Abstract
|
Heather Cartwright |
|
Alexion Gains First Potential Drug for Hypophosphatasia via US$1.08 B Enobia Buyout |
Abstract
|
Heather Cartwright |
|
Amgen Boosts its Oncology Pipeline with US$1.16 B Acquisition of Micromet |
Abstract
|
Heather Cartwright |
|
Watson Strengthens its Presence in Australia and Southeast Asia with Acquisition of Strides Arcolab’s Ascent Pharmahealth |
Abstract
|
Heather Cartwright |
|
Celgene Gains Covalent Drug Pipeline and Platform via Avila Therapeutics Acquisition |
Abstract
|
Heather Cartwright |
|
Valeant Agrees to Buy Eyetech to Strengthen its Ophthalmology Business |
Abstract
|
Heather Cartwright |
|
Biogen Idec Retrieves its Idiopathic Pulmonary Fibrosis Drug via US$562.5 M Stromedix Acquisition |
Abstract
|
Heather Cartwright |
|
Merck & Co. Forms Joint Venture with Supera Farma Laboratorios to Increase its Presence in Brazil |
Abstract
|
Heather Cartwright |
|
Impax In-Licenses US Commercial Rights to AstraZeneca’s Migraine Drug Zomig® |
Abstract
|
Heather Cartwright |
|